tiprankstipranks
Oncolytics Biotech (ONCY)
NASDAQ:ONCY
US Market
ONCY
Oncolytics Biotech
RESEARCH TOOLSreports
Want to see ONCY full AI Analyst Report?

Oncolytics Biotech (ONCY) Earnings Dates, Call Summary & Reports

1,608 Followers

Earnings Data

Report Date
Jul 31, 2026
TBA (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.05
Last Year’s EPS
-0.05
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 4 Analysts Ratings

Earnings Call Summary

Q1 2025
Earnings Call Date:May 14, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant advancements in clinical data and strategic financial moves. The highlights, particularly in clinical trial progress and promising data across several cancer types, outweigh the challenges such as the ongoing CEO search and reduced R&D spending.
Company Guidance
During the first quarter conference call for Oncolytics Biotech in 2025, the company provided guidance on several key metrics related to the development of their cancer therapeutic, pelareorep (pela). They reported cash and cash equivalents of $15.3 million, which is expected to provide financial runway through the third quarter of 2025. Net cash used in operating activities was $6.5 million, a decrease from $7.5 million in the same period last year. General and administrative expenses remained consistent at $3 million, while research and development expenses decreased to $4.1 million from $5.7 million in Q1 2024. The net loss for the quarter was $6.7 million, or $0.08 per share, compared to $6.9 million or $0.09 per share in the previous year. The company also announced a $20 million share purchase agreement with Alumni Capital to extend their financial runway. Oncolytics is advancing their clinical trials, particularly focusing on breast and pancreatic cancer, with promising efficacy data from randomized Phase 2 studies and plans for future registrational opportunities.
Clinical Data Exceeds Expectations
Oncolytics Biotech's clinical data for pelareorep continues to exceed expectations, particularly in difficult-to-treat malignancies such as pancreatic cancer, breast cancer, and anal carcinoma.
Positive Results in Breast Cancer Studies
Pelareorep-based combination therapy substantially outperformed standard care treatments in two randomized Phase 2 studies for HR-positive/HER2-negative metastatic breast cancer.
Promising Pancreatic and Anal Cancer Data
Interim results from the GOBLET Cohort 4 showed a 33% objective response rate in relapsed anal carcinoma, including a complete response lasting over 15 months. Additionally, the pancreatic cancer cohort is progressing with more than half of the required patients enrolled.
Favorable Safety Profile and Versatility
Pelareorep demonstrates a remarkable safety profile and versatility, showing potential in multiple cancer types and combinations with different chemotherapies and checkpoint inhibitors.
Financial Flexibility Through Share Purchase Agreement
A $20 million share purchase agreement with Alumni Capital provides Oncolytics with access to capital, enhancing financial flexibility.

Oncolytics Biotech (ONCY) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

ONCY Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 31, 2026
2026 (Q2)
-0.05 / -
-0.049―――
May 14, 2026
2026 (Q1)
-0.04 / -0.08
-0.056-37.50% (-0.02)――
Mar 30, 2026
2025 (Q4)
-0.06 / >-0.01
-0.07190.00% (+0.06)――
Nov 12, 2025
2025 (Q3)
-0.06 / -0.10
-0.085-16.67% (-0.01)――
Aug 08, 2025
2025 (Q2)
-0.07 / -0.05
-0.07130.00% (+0.02)――
May 14, 2025
2025 (Q1)
-0.07 / -0.06
-0.06311.11% (<+0.01)―
Mar 07, 2025
2024 (Q4)
-0.09 / -0.07
-0.035-100.00% (-0.04)―
Nov 12, 2024
2024 (Q3)
-0.07 / -0.08
-0.09914.29% (+0.01)―
Aug 01, 2024
2024 (Q2)
-0.07 / -0.07
-0.08516.67% (+0.01)―
May 09, 2024
2024 (Q1)
-0.08 / -0.06
-0.07110.00% (<+0.01)―
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ONCY Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
May 14, 2026
$0.87$0.85-2.52%
Mar 30, 2026
$0.81$0.85+5.34%
Nov 12, 2025
$1.14$1.08-4.85%
Aug 08, 2025
$0.92$0.86-6.23%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Oncolytics Biotech (ONCY) report earnings?
Oncolytics Biotech (ONCY) is schdueled to report earning on Jul 31, 2026, TBA (Confirmed).
    What is Oncolytics Biotech (ONCY) earnings time?
    Oncolytics Biotech (ONCY) earnings time is at Jul 31, 2026, TBA (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ONCY EPS forecast?
          ONCY EPS forecast for the fiscal quarter 2026 (Q2) is -0.05.